Stem Cell Therapy
Latin America · 1 shared keyword
Updated
Reviewed by Chandani Patel
Latin America Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$100.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $18.6 Mn | — | — |
| 2025 (base) | $22.5 Mn | +$3.9 Mn | — |
| 2026 (forecast) | $27.1 Mn | +$4.7 Mn | +20.8% |
| 2027 (forecast) | $32.8 Mn | +$5.6 Mn | +45.9% |
| 2028 (forecast) | $39.6 Mn | +$6.8 Mn | +76.3% |
| 2029 (forecast) | $47.9 Mn | +$8.2 Mn | +112.9% |
| 2030 (forecast) | $57.8 Mn | +$10.0 Mn | +157.2% |
| 2031 (forecast) | $69.8 Mn | +$12.0 Mn | +210.7% |
| 2032 (forecast) | $84.4 Mn | +$14.5 Mn | +275.4% |
| 2033 (forecast) | $101.9 Mn | +$17.5 Mn | +353.5% |
| 2034 (forecast) | $123.1 Mn | +$21.2 Mn | +447.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $22.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $123.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 20.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Program, condition and end user (see all) |
| Key players | Illumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.
Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.
The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by ANVISA (Brazil)[1], ARCSA (Ecuador)[2], COFEPRIS (Mexico)[3], ANMAT (Argentina)[4], INVIMA (Colombia)[5] and ISP (Chile)[6]. How care is paid for in some of these countries: the SUS (Brazil)[7]; public care and IESS (Ecuador)[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)[9]; public care, obras sociales and prepaid plans (Argentina)[10]; social health insurance (EPS) (Colombia)[11]; and FONASA and ISAPREs (Chile)[12].
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] ANMAT. Checked 19 Nov 2026.
[5] INVIMA. Checked 19 Nov 2026.
[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.
[7] CONITEC. Checked 14 Nov 2026.
[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.
[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.
[12] FONASA. Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.
What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America
Latin America
Latin America
Latin America
Digital Health · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America
Medical Devices · Latin America
Digital Health · Latin America
Medical Devices · Latin America